Scholarlink

Background <p>Osteoarthritis (OA) is the most common degenerative joint disease and a leading cause of pain and disability worldwide. Currently, the diagnosis and severity of OA are based on clinical and radiological criteria which usually fail to detect the disease early. Syndecan-4 (SDC-4) is a transmembrane heparan sulfate proteoglycan involved in extracellular matrix interactions, inflammatory signaling and regulation of cartilage-degrading enzymes such as ADAMTS-5 and MMPs. The shed, soluble form of SDC-4 has been detected in osteoarthritic synovial fluid and linked to radiographic severity, however evidence on circulating (serum) SDC-4 is more limited, despite its possible role as an early biomarker being involved in OA pathogenesis. The purpose of this study was to evaluate serum SDC-4 concentrations in individuals with knee osteoarthritis (KOA) and to investigate its association with both clinical symptoms and radiological indicators of disease severity.</p> Methods <p>This prospective case-control study was conducted on 45 KOA patients fulfilling EULAR criteria and 45 matched healthy controls. Clinical assessment included WOMAC scores, and physical examination. SDC-4 serum levels were measured using ELISA. Radiographic severity was evaluated by Kellgren–Lawrence (KL) grading, osteophytes, joint space narrowing (JSN), bone contour deformity, and subchondral sclerosis. Statistical analyses included t-tests, ANOVA, and correlation tests.</p> Results <p>Serum SDC-4 levels were markedly increased in KOA patients compared to controls (15.9 ± 7.5 vs. 5.3 ± 2.6 ng/ml, <i>p</i> &lt; 0.001). Higher SDC-4 levels correlated positively with WOMAC pain, stiffness, physical function, and total scores (<i>p</i> ≤ 0.05). Radiographic features including osteophytes, JSN, bone contour deformity, and subchondral sclerosis were all correlated with higher SDC-4 levels (<i>p</i> &lt; 0.001). Moreover, SDC-4 levels increased with higher KL grading, showing significant differences between grades 2, 3, and 4 (<i>p</i> &lt; 0.001).</p> Conclusion <p>Elevated serum SDC-4 is correlated with clinical symptoms and radiographic severity of KOA; thus, SDC-4 could be a potential biomarker for KOA assessment.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Assessment of serum Syndecan-4 in patients with knee osteoarthritis and its correlation with disease severity

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年1月8日

查看全文
  • Ghada Tarek Hegy,
  • Nanis Onsy Neseem,
  • Shereen Salah Metwally,
  • Sherine Abdel Rahman Bassiouni

摘要

Background

Osteoarthritis (OA) is the most common degenerative joint disease and a leading cause of pain and disability worldwide. Currently, the diagnosis and severity of OA are based on clinical and radiological criteria which usually fail to detect the disease early. Syndecan-4 (SDC-4) is a transmembrane heparan sulfate proteoglycan involved in extracellular matrix interactions, inflammatory signaling and regulation of cartilage-degrading enzymes such as ADAMTS-5 and MMPs. The shed, soluble form of SDC-4 has been detected in osteoarthritic synovial fluid and linked to radiographic severity, however evidence on circulating (serum) SDC-4 is more limited, despite its possible role as an early biomarker being involved in OA pathogenesis. The purpose of this study was to evaluate serum SDC-4 concentrations in individuals with knee osteoarthritis (KOA) and to investigate its association with both clinical symptoms and radiological indicators of disease severity.

Methods

This prospective case-control study was conducted on 45 KOA patients fulfilling EULAR criteria and 45 matched healthy controls. Clinical assessment included WOMAC scores, and physical examination. SDC-4 serum levels were measured using ELISA. Radiographic severity was evaluated by Kellgren–Lawrence (KL) grading, osteophytes, joint space narrowing (JSN), bone contour deformity, and subchondral sclerosis. Statistical analyses included t-tests, ANOVA, and correlation tests.

Results

Serum SDC-4 levels were markedly increased in KOA patients compared to controls (15.9 ± 7.5 vs. 5.3 ± 2.6 ng/ml, p < 0.001). Higher SDC-4 levels correlated positively with WOMAC pain, stiffness, physical function, and total scores (p ≤ 0.05). Radiographic features including osteophytes, JSN, bone contour deformity, and subchondral sclerosis were all correlated with higher SDC-4 levels (p < 0.001). Moreover, SDC-4 levels increased with higher KL grading, showing significant differences between grades 2, 3, and 4 (p < 0.001).

Conclusion

Elevated serum SDC-4 is correlated with clinical symptoms and radiographic severity of KOA; thus, SDC-4 could be a potential biomarker for KOA assessment.